REPAMADE V 0.5/0.2 TABLET

Product Description

REPAMADE V 0.5/0.2 TABLET
Composition: Repaglinide 0.5mg + Voglibose 0.2mg

Unlock effective glycemic control with REPAMADE V 0.5/0.2 TABLET, a potent combination therapy designed for Type 2 diabetes management. This pharmaceutical formulation combines the rapid-acting insulin secretagogue Repaglinide with the alpha-glucosidase inhibitor Voglibose, synergistically targeting postprandial blood glucose spikes.

Key Benefits:

• Efficient reduction of post-meal hyperglycemia

• Dual mechanism ensures better overall blood sugar regulation

• Supports improved insulin release and slows carbohydrate absorption

• Suitable for patients requiring enhanced glucose control beyond monotherapy

Ideal For:

• Medical distributors and pharmaceutical retailers seeking a high-demand anti-diabetic product

• Bulk buyers in healthcare institutions looking to stock reliable combination oral hypoglycemic agents

• Hospitals and clinics focusing on comprehensive diabetes care solutions

Usage:
Administer as prescribed by healthcare professionals, typically before meals to maximize efficacy in controlling postprandial glucose levels.